||There have been a number of studies defining a role for PD-L1 in the regulation of immune tolerance and cancer immunity through binding to T cell-expressed PD-1. Interestingly, PD-L1 has also been shown to interact with B7-1, also known as CD80. Like PD- 1:PD-L1 interaction, B7-1:PD-L1 signaling also leads to inhibition of T cell activation, proliferation, and cytokine production, suggesting that this pathway may also serve as a target in cancer immunotherapy and inflammatory diseases.
||The PD-L1:B7-1[Biotinylated] Inhibitor Screening Assay Kit is designed for screening and profiling inhibitors of the PD-L1:B7-1 interaction. The key to this kit is the high sensitivity of detection of biotin-labeled B7-1 by streptavidin-HRP. Only a few simple steps on a microtiter plate are required for the assay. First, PD-L1 is coated on a 96-well plate. Next, B7-1-biotin is incubated with PD-L1 on the plate. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence, which can then be measured using a chemiluminescence reader.
||This kit is useful for screening for inhibitors of PD-L1 binding to B7-1.
||Stable for one year from date of receipt, when stored as directed. Kit components require different storage conditions. Be sure to store each component at the proper temperature upon arrival.
||PD-L1, Fc fusion: 25 µg; -80°C B7-1 (CD80), Fc fusion, Biotin-labeled: 15 µg; -80°C Streptavidin-HRP: 15 µl; +4°C 3x PD-L1 assay buffer: 50 ml; -20°C Blocking buffer: 50 ml; +4°C HRP chemiluminescent substrate A (translucent bottle): 6 ml; +4°C HRP chemiluminescent substrate B (brown bottle): 6 ml; +4°C White 96-well microplate: 1; +4°C